 | Ensure merger and acquisition success - at any point in the M&A processPharmaceutical Mergers and Acquisitions guides you to build an M&A plan that focuses on key goals, avoids costly mistakes, and realizes deal potential as quickly as possible. CEI designed this study to identify the primary drivers of M&A activity. Through the input of pharma industry leaders, our study provides solutions to the greatest M&A pitfalls and gives clear, detailed insight of trends in pharmaceutical deals. The result: a roadmap to the M&A landscape. |
|
 | Adapt to a New Environment and Prove Speaker Programs' ValuePharmaceutical Speaker Programs provides innovative, actionable strategies and best practices that will make your speaker events more effective and generate better ROI. Our data benchmarks - developed from input from marketing executives, brand managers, speaker programs directors among others - will anchor your decisions. The report will help you build a clear and easy case to key stakeholders for speaker programs resource support. |
|
 | Perfect the CRO selection and management process - and guarantee trial successStrategic Clinical Sourcing: Managing Costs and CROs aims to improve your company's clinical outsourcing decision-making during every step of the process - from strategy setting to daily relationship management. Trial cost and timeline benchmarks - coupled with input from leading executives - will show trial teams how to efficiently and effectively manage outsourced trials. |
|
 | Improve Patient Communication and Generate SalesWhat does an effective patient communications program look like? In today's information-hungry environment, it takes more than a company website to motivate patients. Although developing a superior program involves vetting a dizzying number of options, if your brand succeeds, the benefits are palpable: earn customers' trust, win higher brand awareness and loyalty, improve patient adherence, and generate sales. |
|
| Strengthen payer relationships through communication:Of all factors contributing to product success, payer access could be the most critical. Without the best reimbursement status for a drug, the investments your company made during drug development may end up as a lost cause. Securing Market Access: Reimbursement, Payer Relationships and Healthcare Reform examines the processes, strategies and best practices that industry leaders have implemented to build strong relationships and gain payer access. |
|
 | Drive blockbuster revenue with autoimmune breakthroughsThe autoimmune market is proving that the era of the blockbuster is not dead.Of 14 brands already at or expected to reach blockbuster status, half generate at least $3 billion annually. Nine mid-level products will generate $400 million, at minimum, by 2014. For autoimmune drugs, reaching blockbuster-level success is an expectation as much as a goal.Whether you're exploring your options or need to increase your presence in the market, autoimmune compounds provide lucrative opportunities -- don't miss out!From sales projections to clinical trial data to analysts' insights, Autoimmune Market Forecast to 2014 tells you everything you need to know. Unlike other market forecast reports out there, ours covers all of the major indications - rheumatoid arthritis, ulcerative colitis, Crohn's disease, multiple sclerosis, psoriasis and lupus - profiling 40+ drugs and nine leading autoimmune product manufacturers. |
|
 | Improve cost-effectiveness of investigator compensation - and ensure compliance.Establishing transparent and defensible compensation processes for clinical investigators not only saves money - it is absolutely essential in today's restrictive pharma landscape. Regulatory groups, legislative bodies and consumer advocacy groups are applying relentless pressure on commercial relationships with physicians, altering and often limiting industry practices. Now the ripple effect is hitting clinical operations. Some investigations in the area have garnered public attention, with more bound to follow.Cutting Edge Information projects that within five years the same regulatory scrutiny currently on the commercial side will expand to the clinical side. Companies that do not recognize this inevitable reality and formalize their FMV processes today put themselves at great risk for compromised trial results, an audit, financial damage and regulatory scrutiny. Diligence and constant monitoring will go a long way to preventing careless errors and courting potentially dangerous consequences. |
|
 | Rework your sales practices to reach and influence targetsThe "more is better" methodology of selling is dead. The Wall Street Journal now predicts that the number of pharmaceutical sales reps in the US will drop to 70,000 by the year 2015. This is a tremendous change from the boom of the 1990s and early 2000s, when the total number of reps exceeded 100,000.While some companies began adapting a few years ago, other companies now find themselves well behind. For those companies stuck in the past, reducing sales force mirroring, creating more personal relationships with targets, and uncovering new ways to reach physicians are the orders of the day. The companies that will excel will be those that innovate now and find new avenues for connecting with targets and that develop relationships where doctors actually call on reps for information. |
|
 | Perfect the CRO selection and management process - and guarantee trial successClinical Outsourcing Strategy: Selecting Partners and Managing Relationships will guide your company to adopt a proactive approach to avoiding common pitfalls in the clinical trial process. It identifies key questions every trial sponsor should consider before engaging with a client, such as: How does patient recruitment fit into outsourcing strategy? Does this CRO have a reputation for meeting deadlines? Will this CRO's size allow it to meet my needs for a trial? |
|
 | Build a world-class diabetes medical science liaison (MSL) programToday's MSLs are key strategic drivers for diabetes products' and overall company success. Currently, approximately 246 million people worldwide have diabetes; this number is expected to increase to 380 million by 2025, according to the International Diabetes Foundation. Such staggering figures solidify diabetes' position as a primary therapeutic area. They also indicate the value of medical science liaisons who are building relationships within the diabetes medical community. |
|
 | Increase thought leader participation and solidify opinion leader effortsKey Opinion Leaders: Relationship Management and Segmentation Data is an essential tool for thought leader management professionals. This report is a definitive guide for engaging thought leaders in today's increasingly transparent environment. It shows teams how to be proactive and forward-thinking even while feeling the weight of ongoing regulatory pressure. By following this path, beyond building opinion leader relationships, your company will also create a lasting culture of integrity. |
|
 | Thought leader management teams face many new challenges in today's environment. Academic institutions have implemented new regulations limiting or, in some cases, forbidding their faculty's relationships with drug manufacturers. Individual states continue to call for more transparency of the industry's payments to physicians. And industry trade groups, such as PhRMA, and medical associations, such as the ACCME, have revised their guidelines to limit drug makers' involvement in physician activities. |
|
 | Comprehensive Forecasts for Neurodegenerative ConditionsThe neurodegenerative space is a top-selling pharmaceutical market. Consider these facts: * Sales among all drugs profiled in this report total $18.5 billion and are expected to increase 62% to $29.7 billion by 2012. * The majority of this growth is projected to be in multiple sclerosis, which will increase from a $12.6 billion market to upwards of $20 billion in 2012.Neurodegenerative disease patients have few treatment options, which often provide only limited effectiveness. Companies that can invest in and develop new, tolerable therapies which improve patients’ quality of life could see hundreds of millions — or even billions — of dollars in sales. |
|
 | Reinvent Your Medical Information Call Centers: * Are your call loads decreasing because customers seek information via new avenues? * Do you face info-sharing competition within your own organization? * What new areas demand medical information expertise?Evolving Medical Information Call Centers addresses these questions — and more — to give your company the boost needed to correct your call centers’ mistakes and evolve the group into new territories. Our study contains real-world data and best practices from top pharmaceutical companies’ medical information call center operations. |
|
 | Comprehensive Forecasts AND Detailed Budget BenchmarksCutting Edge Information's new report, "Oncology Roadmap," explores the fiercely competitive oncology market in a way that no other available forecast can match. |
|
 | Ensure brand sales success — make the right investment choices at the right time : * Would you like to take the guesswork out of spending on brand commercialization efforts? * Are you sure when and how much to invest in brand promotional activities, market research, reimbursement efforts and medical affairs initiatives?Driving Successful Pharma Brands addresses these questions — and more — to give you the information you need to avoid costly mistakes and propel brands’ bottom-line success. |
|
 | Strengthen Market Research's Profile and Impact:Tightening markets, generic encroachment, slowing revenue streams and frequent clinical failures have left pharmaceutical companies treading carefully in efforts to find the next profitable drug. Companies are now trying to determine the correct markets to enter at the earliest positive clinical signs. |
|
 | Comprehensive Diabetes ForecastWhich companies are poised to dominate the diabetes market? With new classes on the rise, which innovative therapies will make an impact? How will clinical results and safety issues affect drug profitability over the long term?CEI’s veteran analysts answer these questions — and more — by placing critical drug information in a relevant industry-wide context. Other reports skim the surface, examining only top drugs at top companies. Ours is complete, covering marketed brands, pipeline products, clinical development, whole drug classes and top drug manufacturers — all in one, easy-to-read format. |
|
 | Optimize pricing planning to satisfy customer group needs:The pricing landscape has changed dramatically over the past decade. In the 1990s and even a few years ago, pricing was almost an afterthought — pricing plans were formed and carried out during ramp-up to product launch; there was less regulatory scrutiny; the concept of health outcomes analysis was still taking shape, and any pharmacoeconomic data that companies were able to provide was better than none. |
|
 | Drive revenue through alliance success:Nearly half of today’s top-selling drugs were the result of partnerships. Companies across the industry annually spend hundreds of millions of dollars to utilize other firms’ discovery, development and marketing capabilities in their quests for the next blockbusters. |
|
 | Refine processes to accelerate and improve clinical trialsExecuting a successful clinical trial requires seamless communication and coordination among many stakeholders–study sponsors, contract research organizations, academic research organizations, site management organizations, patient recruiters, clinical investigators and patients. |
|
 | Give Your Team Access to the Most Comprehensive Oncology Forecast Ever CreatedCutting Edge Information's new report, "Oncology Market Forecast to 2013," explores the fiercely competitive oncology market in a way that no other available forecast can match. |
|
| Improve meeting planning efficiency to win physician attendanceIn today’s competitive environment, meeting planners in the life sciences industries are increasingly required to take on greater responsibilities. No longer relegated to marketing support personnel, meeting planners now play a strategic role. To bolster this transition, most companies employ centralized structures for their meeting planning departments. More than ever before, meeting planners interact with and serve an entire organization. |
|
| Close key deals and build a top-flight business development team:Deal-making is an established strategy for filling company pipelines, raising cash, expanding portfolios and driving long-term revenue. Whether companies forge straightforward licensing agreements or long-term alliances, organizations across the industry depend on other firms’ discovery, development and marketing capabilities to reach a range of different objectives. |
|
| Solidify competitive intelligence’s presence to optimize decision makingPharmaceutical competitive intelligence (CI) helps drive decision-making processes across an organization. As a forward-thinking, proactive support function, CI influences business development and brand management, among other areas. CI identifies market risks as well as business growth opportunities. |
|
| Revolutionize your MSL teams to help drive bottom-line results:In the past, medical science liaisons (MSLs) served a traditional role as scientific support to sales. But market realities, including fewer drug approvals and increasing regulatory demands, have led companies to put a premium on building productive relationships with key opinion leaders and supporting company objectives through medical education. |
|
| Compliance is at the forefront of pharma companies’ minds today. Companies face the threat of staggering fines and increased scrutiny from regulatory bodies. A growing level of public distrust of the industry also carries a negative effect on companies’ reputations. These events have created a new regulatory environment that has dramatically affected companies’ organizational structures and practices. In fact, the industry’s most influential companies have reexamined—and sometimes reinvented—the way they do business. |
|
| Increase the effectiveness of your medical affairs efforts:Medical affairs plays an instrumental role in providing medical and scientific perspectives for a company’s brands. While the function has long been considered vital, recent years have brought tremendous change. Pressure to remain compliant and increasing globalization have had a profound impact on companies’ medical affairs structures, budgets and strategies. This transition is exciting—it creates a motivator for dynamic growth opportunities that underscore medical affairs’ importance to pharma companies. At the same time, such growth spurs new challenges. Medical affairs teams often struggle to strike a balance— between serving both internal and external customers, as well as being faithful to clinical truths and contributing to commercial goals. |
|
| Establish and perfect internal controls to capitalize on IIT opportunities Investigator-initiated clinical trials (IITs) provide companies with the clinical data to further scientific understanding of their drugs. IIT findings help to expand on- and off-label usage, reach new patient populations, generate data for publication and solidify relationships with key opinion leaders. Once considered an afterthought, IITs are now often regarded as critical pieces of product development strategy. Reflecting this different mindset, many companies have established centralized IIT management groups and processes. While such efforts mark a giant step forward, all organizations still routinely confront challenges that range from slowdowns in the IIT-approval process to issues with trial oversight. |
|
| Increase the effectiveness of your LCM Strategies: With pipelines diminishing and generics becoming more aggressive, pharmaceutical companies must maximize their brands’ value and time on the market. Strategic and well-orchestrated lifecycle management efforts are crucial to maintaining a brand’s long-term health. |
|
| Explore detailed segmentation data, budgets and headcounts for thought leader management and MSL programs:Identifying and recruiting key opinion leaders is a challenging task in and of itself. But what are the best strategies to retain those relationships once companies have established them? Cutting Edge Information answers this question and more in its latest study on key opinion leader management organizations. |
|
| In Canada, access to physicians remains one of the top problems of the day for pharmaceutical sales organizations. Though not nearly as overrun as US doctors, top prescribing Canadian physicians can still expect to see as many as 4 to 6 different reps from some larger companies during a given month. |
|
